BMC Cancer

Table 6 Expression of CNKSR2 relative to ER, PR and HER2 status in non-malignant and malignant breast tumors

From: Regulation of CNKSR2 protein stability by the HECT E3 ubiquitin ligase Smurf2, and its role in breast cancer progression

		Non-Malignant	Malignant	P-value
		(n = 22)	(n = 62)
CNKSR2	ER
no/mild	no/mild	14(63.64%)	8(12.9%)	< 0.001
no/mild	mod/intense	3(13.64%)	0(0.00%)
mod/intense	no/mild	2(9.09%)	36(58.06%)
mod/intense	mod/intense	3(13.64%)	18(29.03%)
CNKSR2	PR
no/mild	no/mild	14(63.64%)	8(12.9%)	< 0.001
no/mild	mod/intense	3(13.64%)	0(0.00%)
mod/intense	no/mild	2(9.09%)	36(58.06%)
mod/intense	mod/intense	3(13.64%)	18(29.03%)
CNKSR2	HER2
no/mild	no/mild	14(63.64%)	3(4.84%)	< 0.001
no/mild	mod/intense	3(13.64%)	5(8.06%)
mod/intense	no/mild	2(9.09%)	24(38.71%)
mod/intense	mod/intense	3(13.64%)	30(48.39%)

Back to article page

ISSN: 1471-2407

Contact us

Submission enquiries: bmccancer@biomedcentral.com
General enquiries: ORSupport@springernature.com